Emcure Pharmaceuticals Ltd was founded by Satish Mehta in 1983. Satish Mehta is a postgraduate from IIM Ahmedabad. Emcure's marketing team comprises of a field force of more than 1,000 detail men (Medical Representatives), five branch offices and 27 distribution centers and cover the entire length and breadth of India. They visit at least 1,50,000 doctors and same number of retailers every month.
Emcure is recognized for its world class R&D center, which has the accreditation of Department of Scientific Industrial Research (DSIR). It has emerged as one of the pioneers in the field of New Drug Delivery System (NDDS) in India. Emcure is working very closely with National Chemical Laboratories (NCL) on Chiral technology. Its six manufacturing facilities located at Bhosari near Pune are comparable to the best in the country and enjoy ISO 9002 and WHO certification.
Emcure has also entered the biotechnology field with the introduction of Erythropoietin, which in turn will be followed by number of high-tech biotechnology products, many of them, for the first time in India.
Emcure has a global vision. Emcure wishes to be a major player not only in the domestic market but also in the international market. It is already exporting their products to 25 countries and further registration in 30 other countries is on the cards. Emcure has acquired 14 acres land at a prestigious location at Pune where state-of-the-art manufacturing facility is being set up.
The Emcure Group is associated with major multinationals like Pfizer, Glaxo, Novartis and Aventis. On account of alliances with these multinationals, it has emerged as one of the largest pharmaceutical manufacturer in India.
Emcure is one of the fastest growing pharmaceutical companies in India (Source: ORG-Indian IMS) on account of launch of innovative formulations developed by its R&D and marketing strategies designed to build brands. Current Group turnover is Rs 320 crore
It has its presence in most of the major therapeutic segments such as Cardiology, Nephrology, Gastroenterology, Anti-infectives etc. Over the last five years, the company has recorded an average CAGR of 42 % and has improved its ranking by Market Research Agency from 128th in the year 1995-96 to 32nd by the end of July 2002.
Emcure Biotech Limited
Emcure Biotech Limited is a joint venture between Emcure Pharmaceuticals Limited and Ablemax Inc., British Virgin Island.
In this joint venture, the technology is being provided by Ablemax. The joint venture would manufacture starting all the way from Cell culture products such as TNK-TPA and GM-CSE. The entire Research and development and manufacturing activities would be carried out at the proposed facility at Hinjewadi.